An interventional study of Preoperative optimisation program in Prehabilitation, Pancreas Cancer and Surgery, sponsored by Maastricht University Medical Center. Recruiting at 13 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Pancreatic Neoplasms with a site in Netherlands — 22 open to participants now, 34 under way, 6 of them phase 3. Pancreatic Neoplasms · Netherlands.
Among the 106 studies in Pancreatic Neoplasms with a site in Netherlands, this one is the 2nd largest by planned enrollment of the 89 interventional ones that give a count, is one of 8 that started in 2024, is one of 26 with no phase, reaches primary completion later than 22 of the 33 other live ones, and was the 84th registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →22 of the 106 studies in Pancreatic Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
Revolution Medicines, Inc. · Sites in Netherlands, United States, Austria and 2 more countries
Ages 18+
Incyte Corporation · Sites in Netherlands, United States, Australia and 19 more countries
Ages 18+
Revolution Medicines, Inc. · Sites in Netherlands, United States, Australia and 18 more countries
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 35 · Phase 3 17 · Phase 4 1
First in 1999; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,575 is above the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 97 across the 89 interventional studies, 223 across the 15 observational. Of the 58 that completed or were terminated, 12 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 106 have an industry lead sponsor. The 10 most frequent:
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
Maastricht University Medical Center has 5 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
8 of the studies in Pancreatic Neoplasms with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04927780Phase 3Erasmus Medical CenterPerioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer | 2027-01 |
| NCT05927142Joachim Aerts, MD PhDCombining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy | 2026-12 |
| NCT07796594Amsterdam UMC, location VUmcIntegration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in Cancer | 2026-12-31 |
| NCT02912949Partner Therapeutics, Inc.A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | 2026-12-31 |
| NCT04954599Maastricht University Medical CenterPhase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | 2027-02 |
Add all 8 to your calendar (.ics) → With an account.
Among the 106 studies in Pancreatic Neoplasms with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this stepped-wedge randomized controlled trial is to investigate whether implementation of a best practice program for preoperative optimisation (prehabilitation program) with a focus on screening, assessment, and intervention of 8 potentially (partly) modifiable risk factors in patients with (suspected) pancreatic cancer will improve outcome. The main questions it will aim to answer are:
Background In the past, little attention has been given in the daily practice to the patient's condition before an operation. Recent studies have shown the benefit of preoperative optimisation programs. However, these studies consisted only of smaller studies and were mainly performed in patients who underwent colorectal surgery. Although promising, unfortunately, strong evidence to support the contribution of prehabilitation to optimize the functional outcome after surgery is still lacking and consequently it is not included in the Dutch basic health insurance package.
Objective To investigate whether implementation of a best practice program for preoperative optimisation of patients with a focus on screening, assessment, and intervention of 8 potentially (partly) modifiable risk factors (low (aerobic) fitness level, malnutrition, low psychological resilience, comorbidities (iron deficiency (anaemia), impaired glucose control and frailty), and intoxications (alcohol and smoking behaviour)) will improve the time to functional recovery.
Study design A nationwide stepped-wedge cluster randomized trial. In this design all participating centres will cross over from current practice to the best practice program, in a randomised order. At the end of the study, all centres will have implemented the best practice program.
Study population 13 centres performing major pancreatic surgery in the Netherlands collaborating within the Dutch Pancreatic Cancer Group (DPCG).
Intervention Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed. This program is based on findings in previous screening and prehabilitation programs, a national inventory of current preoperative care protocols and expert opinion. Consensus upon this program was reached with pancreatic surgeons from all centres of the DPCG. The final program was critically reviewed by the advisory committee of internationally respected experts in the field of prehabilitation and pancreatology.
Comparison Preoperative care according to current practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receiving standard preoperative care
Implementation of best practice preoperative optimisation program
Behavioral: Preoperative optimisation program
Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed
Time to functional recovery
Functional recovery is achieved when all of the following five criteria are met: a) restored level of mobility at the preoperative level, b) sufficient pain control with oral medication alone, c) ability to maintain at least 50% daily required energy intake, d) no intravenous fluid administration, and e) no clinical signs of infection.
Time frame: On average 6-10 days
Comprehensive Complication Index (CCI)
The CCI is calculated as the sum of all complications that are weighted for their severity, with a range from 0 to 100, whereby a higher score indicates presence of more complications and/or more severe complications.
Time frame: 30 days postoperative
Length of hospital stay
Length of hospital stay of the primary admission, measured in days
Time frame: On average 2 weeks postoperative
Readmissions
Readmissions within 30 days after discharge
Time frame: 30 days after discharge of primary admission
Postoperative complications
Any postoperative complication
Time frame: During primary admission, on average 14 weeks postoperative
Incremental cost-effectiveness ratio (ICER)
The difference in costs between standard care and best practice care divided by the difference in health benefits, measured in quality-adjusted life years (QALYs).
Time frame: 1 year postoperative
Evaluation of health status
Reported health status measured with questionnaire EQ-5D-5L
Time frame: At baseline, 3 months and 12 months postoperative
Evaluation of quality of life for cancer patients
Reported quality of life measured with questionnaire EORTC QLQ-C30
Time frame: At baseline, 3 months and 12 months postoperative
Plan to share: Yes — All of the individual participant data collected during the trial will be shared, after deidentification upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Beginning 3 months and ending 5 years following article publication
Access criteria: Data will be available upon request. Request should be directed to marcel.den.dulk@mumc.nl.
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.
Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 36 months is below that.
Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center →